Claims
- 1. An isolated RIP-Thr514 polypeptide, comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:2, which consecutive amino acid residues comprise the amino acid residue 514 (Thr) of SEQ ID NO:2.
- 2. An isolated polypeptide according to claim 1, wherein said polypeptide has an activity selected from at least one of: a kinase or kinase inhibitory activity or a RIP-binding or binding inhibitory activity.
- 3. A method of screening for an agent which modulates the interaction of a RIP polypeptide to a binding target, said method comprising the steps of:incubating a mixture comprising: an isolated polypeptide according to claim 1, a binding target of said polypeptide, and a candidate agent; under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity; detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.
- 4. A method according to claim 3, wherein said binding target is a natural intracellular substrate of the polypeptide and said agent-biased binding affinity is detected as phosphorylation of said substrate.
- 5. A method according to claim 3, wherein said binding target comprises a Tumor necrosis factor receptor Associated Factor-2 (TRAF2) or a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD).
- 6. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ1 (SEQ ID NO:2, residues 509-518).
- 7. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ2 (SEQ ID NO:2, residues 514-521).
- 8. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ3 (SEQ ID NO:2, residues 506-514).
- 9. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ4 (SEQ ID NO:2, residues 504-524).
- 10. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ5 (SEQ ID NO:2, residues 498-514).
- 11. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ6 (SEQ ID NO:2, residues 514-534).
- 12. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ7 (SEQ ID NO:2, residues 513-520).
- 13. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ8 (SEQ ID NO:2, residues 508-515).
- 14. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ9 (SEQ ID NO:2, residues 512-522).
- 15. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ10 (SEQ ID NO:2, residues 423-514).
- 16. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ11 (SEQ ID NO:2, residues 423-543).
- 17. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ12 (SEQ ID NO:2, residues 423-579).
- 18. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ13 (SEQ ID NO:2, residues 423-633).
- 19. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ14 (SEQ ID NO:2, residues 423-671).
- 20. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ15 (SEQ ID NO:2, residues 514-543).
- 21. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ16 (SEQ ID NO:2, residues 514-579).
- 22. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ17 (SEQ ID NO:2, residues 514-633).
- 23. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise αΔ18 (SEQ ID NO:2, residues 514-671).
- 24. An isolated polypeptide according to claim 1, wherein said consecutive amino acid residues comprise SEQ ID NO:2.
CROSS-REFERENCE TO RELATED APPLICATION
This is a CIP of claims priority under 35USC120 to U.S. patent application Ser. No. 08/553,727, filed Oct. 23, 1995 now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5674734 |
Leder et al. |
Oct 1997 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/553727 |
Oct 1995 |
US |
Child |
09/132118 |
|
US |